Trial
NCT02982694
Study With Atezolizumab Plus Bevacizumab in Patients With Chemotherapy Resistant, MSI-like, Colorectal Cancer
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Vall d'Hebron Institute of Oncology
Collaborators
European Organisation for Research and Treatment of Cancer - EORTC
Condition
MSI
Intervention
Atezolizumab
Why stopped
The results of the interim analysis showed that the efficacy in the MSS subgroup (MSI like) is inferior to the expected, and this situation is very unlikely to be reversed if the trial is fully completed.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-01